Cabaletta Bio Financials - Benzinga

Cabaletta Bio Inc

CABANASDAQ

Trade with Public

Trade with Public

$2.11

-0.049-2.27%

最終更新: Sep 25, 10:25 AM

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

Cabaletta Bio Financials

Cabaletta Bio (CABA) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Cabaletta Bio Q2 EPS $(0.34) Beats $(0.39) Estimate

Cabaletta Bio (NASDAQ:CABA) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.39) by 12.82 percent. This is a 53.42 percent increase over losses of $(0.73) per share from

Benzinga Newsdesk

PRO
Cabaletta Bio Q1 EPS $(0.39), Inline

Cabaletta Bio (NASDAQ:CABA) reported quarterly losses of $(0.39) per share which met the analyst consensus estimate. This is a 45.07 percent increase over losses of $(0.71) per share from the same period last year.

Benzinga Newsdesk

PRO
Cabaletta Bio Q4 EPS $(0.40) Beats $(0.47) Estimate

Cabaletta Bio (NASDAQ:CABA) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.47) by 13.98 percent. This is a 38.46 percent increase over losses of $(0.65) per share from the

Benzinga Newsdesk

PRO
Cabaletta Bio Q3 EPS $(0.44) Beats $(0.45) Estimate; Cash, Cash Equivalents And Short-Term Investments Of $159.9M Provides Cash Runway Into 2H 2026

Benzinga Newsdesk

PRO
Cabaletta Bio Q2 EPS $(0.73) Misses $(0.61) Estimate

Benzinga Newsdesk

PRO
Cabaletta Bio Q4 2024 GAAP EPS $(0.65) Misses $(0.63) Estimate, Operational Runway Into 1H26 With Cash And Cash Equivalents Of $164M As Of December 31, 2024

Cabaletta Bio (NASDAQ:CABA) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.63) by 3.17 percent. This is a 41.3 percent decrease over losses of $(0.46) per share from the

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved